| Document |
Document Title |
|
JP2008214356A |
To prevent angiogenesis and to cure or prevent undesirable cell proliferation including a tumor.The invention relates to a composition and a method for inhibiting a hedgehog route by using an antagonist for the hedgehog route, for exampl...
|
|
JP4146897B2 |
Multiple novel reaction schemes, novel process steps and novel intermediates are provided for the synthesis of epoxymexrenone and other compounds of Formula I wherein: -A-A- represents the group -CHR4-CHR5- or CR4-CR5- R3, R4 and R5 are ...
|
|
JP2008534623A |
The present invention relates to methods and compositions for treating, preventing or reducing the risk of developing a mitochondrial disorder or disease or the symptoms associated with a mitochondrial disorder or disease.
|
|
JP2008195704A |
To elucidate pharmacological action of Withanone contained in Withania somnifera leaf extract and provide a composition for new medicinal application and health application, based on the pharmacological action.The composition for lifetim...
|
|
JP2008528656A |
Triterpenic alkaloids (I) and their addition salts, isomers, enantiomers and/or diastereomers are new. Triterpenic alkaloids of formula (I) and their addition salts, isomers, enantiomers and/or diastereomers are new. R 1-CH 2X 1R 7, -CH=...
|
|
JP4115656B2 |
It is intended to provide a substance which is efficacious in whitening sun-burnt skin after UV irradiation and preventing, ameliorating and treating skin pigmentation (for example, spots and freckles caused by sunburn, liver spots) and ...
|
|
JP2008522983A |
The invention encompasses processes for synthesizing 1-[17²-acetyloxy-3±-hydroxy-2²-(4-morpholinyl)-5±-andros
tan-16²-yl]-1-(2-propenyl)pyrrolidinim bromide (rocuronium bromide) and intermediates thereof.
|
|
JP2008127378A |
To provide medicines and foods having inhibiting action against differentiation and/or proliferation of an osteocrastic cell.These are medicines or foods having inhibiting action against differentiation and/or proliferation of an osteocr...
|
|
JP2008519020A |
The invention provides sarsasapogenin in novel amorphous, crystalline, solvated and hydrated forms, and the use thereof in manufacturing pharmaceutical or edible grade sarsasapogenin and its derivatives
|
|
JP4095018B2 |
A process for the preparation of high purity flumethasone in high yield involves C3 protecting 9,11beta-epoxy-17alpha,21-dihydroxy-16alpha-methylpregna-1,4
-diene-3,20-dione,21-acetate, fluorinating at 6alpha, removing the C3 protecting ...
|
|
JP2008516972A |
The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a disorder or disease related to, or the symptoms associated with a neurodegenerative disorder suc...
|
|
JP2008100996A |
To synthesize epoxymexrenone and an epoxymexrenone-based compound.Multiple novel reaction schemes, novel process steps and novel intermediates are provided for the synthesis of epoxymexrenone compounds of the formula I, wherein: -A-A- re...
|
|
JP4076098B2 |
Process for preparing the compound 11beta-21-dihydroxy-2'-methyl-5'betaH-pregna-1,4-dieno[17,16
-d]oxazoline-3,20-dione of formula (I):which comprises adsorbing said compound, contained into an aqueous solution resulting from fermentatio...
|
|
JP4076097B2 |
A process for preparing the compound (11beta,16beta)-21-(3-CARBOXY-1-OXOPROPOXY)-11-HYDROXY-2'-ME
THYL-5'H-PREGNA-1,4-DIENO(17,16-D) OXAZOLE-3,20-DIONE which comprises reacting the compound (11beta,16beta)-11,21-DIHYDROXY-2'-METHYL-5'H-P...
|
|
JP4065399B2 |
Compounds of formula (I), where R is a monovalent cyclic organic group having from 3 to 15 atoms in the ring system, useful as pharmaceuticals
|
|
JP2008506649A |
Compounds of formula I in free or salt form, wherein R1 and R2 have the meanings as indicated in the specification, are useful for treating inflammatory conditions, particularly inflammatory or obstructive airways diseases. Pharmaceutica...
|
|
JP4039683B2 |
A codrug composition of at least two drug compounds covalently linked to one another via a labile bond to form a single codrug composition, and methods of use of the codrug for the treatment of various medical conditions. The codrug may ...
|
|
JP2007537131A |
Pharmaceutical compositions for and methods of preventing infection or treating an individual who has been identified as being infected with a Flavivirus, Pestivirus, picornovirus or coronavirus such as HCV, GB virus B, JEV, WNV, CSFV, B...
|
|
JP2007326855A |
To provide a new material useful as an antitumor agent, a cardiotonic drug and an anticancer agent-sensitive enhancer, and a production method of the material from a plant. The new steroid-type cardiotonic glycoside represented by genera...
|
|
JP2007536194A |
The present invention includes not only phosphorus-substituted compounds having immunomodulatory activity, compositions containing such compounds, and therapeutic methods, which include the step of administering such compounds, but also ...
|
|
JP4016070B2 |
PCT No. PCT/EP96/05390 Sec. 371 Date Jun. 5, 1998 Sec. 102(e) Date Jun. 5, 1998 PCT Filed Dec. 4, 1996 PCT Pub. No. WO97/21722 PCT Pub. Date Jun. 19, 1997A process for preparing the compound (11 beta ,16 beta )-21-(acetyloxy)-11-hydroxy-...
|
|
JP2007534736A |
The invention provides smilagenin in novel crystalline, hydrated forms, and the use thereof in manufacturing pharmaceutical or edible grade smilagenin and its derivatives.
|
|
JP4015206B2 |
A process for the production of medrogestone, in which, in an intermediate step, the solvate 3β,5α,6β-trihydroxy-6α,17α-dimethylpregnan-20-one monomethanolate is obtained as a solid, stable compound by displacing the organic solvent...
|
|
JP2007302684A |
To provide a compound for use in the treatment of an inflammatory or obstructive airway disease, a method for producing the same, and a medicament containing the same. Provided is a medicament comprising, separately or together, (A) a co...
|
|
JP2007533706A |
The invention relates to a new method of treatment of respiratory diseases, in particular the treatment of asthmatic smoking patients. The method comprises the administration of a pharmaceutical composition comprising ciclesonide.
|
|
JP4011142B2 |
|
|
JP4011140B2 |
|
|
JP2007530557A |
Processes are described for epoxidation reactions. In particular, the process comprises the conversion of a steroid substrate having an olefinic unsaturation in the steroid nucleus to a structure comprising a 9,11-epoxy substituent by re...
|
|
JP2007527381A |
The invention relates to a novel procedure for the production of a high yield of small crystalline particles of a narrow size distribution.
|
|
JP3983796B2 |
This invention provides a simplified method for converting pregnan-3,20-dione compounds to 3 alpha -hydroxy,3 beta -substituted-pregnanes. By selective use of reagents the unprotected dione is converted chemoselectively and diastereosele...
|
|
JP2007238624A |
To provide an anti-cancer phosphonate analogue, relating to compounds having anti-cancer activity. By a method and a composition which make cells accumulate or hold a biologically active medicine in them, cell targeting can be done. The ...
|
|
JP3977462B2 |
The invention relates to a 11-(substituted phenyl)-estra-4,9-diene derivative of formula I wherein A is a residue of a 5- or 6-membered ring containing 2 heteroatoms which are not connected to each other and independently selected from O...
|
|
JP2007223940A |
To provide new chemical ingredients as un-utilized resources. This compound is obtained by extracting the carpophores of Trichia favoginea var. persimilis with methanol and acetone, gathering the extracts, distilling away the solvents fr...
|
|
JP3972103B2 |
|
|
JP2007210987A |
To provide an agent for preventing or treating viral myocarditis and viral diseases related to the viral myocarditis. This agent for preventing or treating the viral diseases contains a compound represented by the general formula (1) (-A...
|
|
JP2007210888A |
To provide a new method for producing a steroid compound. The present invention provides a method for producing 5β-3,7-dioxocholanic acid or its ester derivative by passing through the following four steps (I) to (IV) by using cholesta-...
|
|
JP3950489B2 |
PURPOSE: To obtain the subject compound used for betamethasone source material, etc., by dehydrating a 17α-hydroxy-17β-cyanoandrosta-diene-3-one to an novel intermediate, bringing a CN group to a methyl ketone and methylating after epo...
|
|
JP2007520496A |
A pharmaceutically acceptable composition comprising an anti-inflammatory steroid or pharmaceutically acceptable salt thereof, which exists in varying crystal and crystal composite sizes wherein the proportion of crystals and crystal com...
|
|
JP3940928B2 |
To provide a plant-derived water-soluble extract comprising substantially at least 60% to 90% of solamargine and solasonine, its preparing method and a composition to inhibit tumor/cancer cells containing it. The water-soluble extract de...
|
|
JP2007145849A |
To provide a pharmacological composition containing a water-soluble extract originated from a plant as an effective component for suppressing the proliferation of a tumor cell or cancer cell, specially liver cancer cell, lung cancer cell...
|
|
JP2007119500A |
To provide a method for producing 3β,5α,6β-trihydroxy-6α,17α-dimethylpregnan-20-one monomethanolate.The method for producing 3β,5α,6β-trihydroxy-6α,17α-dimethylpregnan-20-one monomethanolate comprises displacing the solvent of ...
|
|
JP3913475B2 |
Sulfatase inhibitor compounds useful in the treatment of estrogen dependent illnesses are disclosed. These compounds generally comprise a steroid nucleus substituted at the C17 position. Methods for synthesizing these compounds and using...
|
|
JP2007506681A |
The present invention provides a method of treating respiratory and allergic diseases. In particular, it provides a method for the treatment of asthma comprising administering to a subject a therapeutically effective amount of a pharmace...
|
|
JP2007016043A |
To provide an aldosterone receptor antagonist drug eplerenone having a new crystalline form which exhibits relatively high physical stability at normal temperatures of storage and use.A process for preparing Form L crystalline eplerenone...
|
|
JP2006524664A |
The present invention relates to the chemical synthesis of solanum glycosides, in particular to the synthesis of solasonine as well as to novel beta-monosaccharide intermediate compounds, of Formula (2), where R1 is a benzylidene, 4-nitr...
|
|
JP2006523665A |
Use of a compound of formula (I) or a 3-enol C1 to 4 alkanoate ester thereof in the manufacture of a medicament for the treatment of an angiotensin II related disease in humans and animals wherein R1, R2, R5, R6 are the same or different...
|
|
JP3834060B2 |
The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human vomeropherin, e.g. a pregnane steroid, or a pharmaceutical composition containing a vomeropherin, su...
|
|
JP2006520802A |
A steroid comprising a 17-spirolactone or corresponding open lactone structure is obtained by carbonylation of a 17-alkenyl or 17-alkynyl substrate. A 17-alkenyl intermediate may be prepared by semi-hydrogenation of a 17-alkynyl group. M...
|
|
JP2006520791A |
A method of inhibiting the hyperproliferation of malignant or neoplastic cells, comprising treating the cells with an antiproliferative amount of 1alpha,24(S)-dihydroxyvitamin D2. The method also includes the co-administration of cyotoxi...
|
|
JP3816004B2 |
An improved process and composition are disclosed for isolation of steroids containing a 5,7-diene functionality from a sterol mixture that comprises formation of a Diels-Alder reaction product of the ster-5,7-dienol in the presence of a...
|
